Codexis and Nitto Denko Avecia Partner to Evaluate ECO Synthesis Platform for siRNA Manufacturing

Reuters

Oct 29

<a href="https://laohu8.com/S/CDXS">Codexis</a> and <a href="https://laohu8.com/S/NDEKF">Nitto Denko</a> Avecia Partner to Evaluate ECO Synthesis Platform for siRNA Manufacturing

Codexis Inc., a leader in enzymatic solutions for therapeutics manufacturing, has entered into an evaluation agreement with Nitto Denko Avecia, a leading contract development and manufacturing organization specializing in oligonucleotide therapeutics. Under the agreement, Nitto Denko Avecia will assess Codexis' ECO Synthesis® Manufacturing Platform, an enzyme-catalyzed technology designed to replace traditional solid-phase oligonucleotide synthesis. The collaboration aims to pave the way for future licensing discussions and broader adoption of the ECO Synthesis platform, advancing scalable and sustainable manufacturing of therapeutic siRNA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN10188) on October 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579047239"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579047239\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579047239?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 21:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579047239","market":"nz","top_or_hot":-1,"title":"Codexis and Nitto Denko Avecia Partner to Evaluate ECO Synthesis Platform for siRNA Manufacturing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CDXS\">Codexis</a> and <a href=\"https://laohu8.com/S/NDEKF\">Nitto Denko</a> Avecia Partner to Evaluate ECO Synthesis Platform for siRNA Manufacturing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Codexis Inc., a leader in enzymatic solutions for therapeutics manufacturing, has entered into an evaluation agreement with <a href=\"https://laohu8.com/S/NDEKY\">Nitto Denko</a> Avecia, a leading contract development and manufacturing organization specializing in oligonucleotide therapeutics. Under the agreement, Nitto Denko Avecia will assess Codexis' ECO Synthesis® Manufacturing Platform, an enzyme-catalyzed technology designed to replace traditional solid-phase oligonucleotide synthesis. The collaboration aims to pave the way for future licensing discussions and broader adoption of the ECO Synthesis platform, advancing scalable and sustainable manufacturing of therapeutic siRNA.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN10188) on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Codexis and Nitto Denko Avecia Partner to Evaluate ECO Synthesis Platform for siRNA Manufacturing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCodexis and Nitto Denko Avecia Partner to Evaluate ECO Synthesis Platform for siRNA Manufacturing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-29 21:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CDXS\">Codexis</a> and <a href=\"https://laohu8.com/S/NDEKF\">Nitto Denko</a> Avecia Partner to Evaluate ECO Synthesis Platform for siRNA Manufacturing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Codexis Inc., a leader in enzymatic solutions for therapeutics manufacturing, has entered into an evaluation agreement with <a href=\"https://laohu8.com/S/NDEKY\">Nitto Denko</a> Avecia, a leading contract development and manufacturing organization specializing in oligonucleotide therapeutics. Under the agreement, Nitto Denko Avecia will assess Codexis' ECO Synthesis® Manufacturing Platform, an enzyme-catalyzed technology designed to replace traditional solid-phase oligonucleotide synthesis. The collaboration aims to pave the way for future licensing discussions and broader adoption of the ECO Synthesis platform, advancing scalable and sustainable manufacturing of therapeutic siRNA.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN10188) on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDXS","symbol_name":"Codexis","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL3V9NYb:1","article_id":"2579047239","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579047239","pubTimestamp":1761746354,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Codexis Inc., a leader in enzymatic solutions for therapeutics manufacturing, has entered into an evaluation agreement with Nitto Denko Avecia, a leading contract development and manufacturing organization specializing in oligonucleotide therapeutics. Under the agreement, Nitto Denko Avecia will assess Codexis' ECO Synthesis Manufacturing Platform, an enzyme-catalyzed technology designed to replace traditional solid-phase oligonucleotide synthesis. The collaboration aims to pave the way for future licensing discussions and broader adoption of the ECO Synthesis platform, advancing scalable and sustainable manufacturing of therapeutic siRNA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDXS":"Codexis","BK4121":"生命科学工具和服务"},"translate_title":"Codexis和Nitto Denko Avecia合作评估用于siRNA制造的ECO合成平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDXS":0.9},"content_text":"Codexis and Nitto Denko Avecia Partner to Evaluate ECO Synthesis Platform for siRNA Manufacturing\n    \n\n        Codexis Inc., a leader in enzymatic solutions for therapeutics manufacturing, has entered into an evaluation agreement with Nitto Denko Avecia, a leading contract development and manufacturing organization specializing in oligonucleotide therapeutics. Under the agreement, Nitto Denko Avecia will assess Codexis' ECO Synthesis® Manufacturing Platform, an enzyme-catalyzed technology designed to replace traditional solid-phase oligonucleotide synthesis. The collaboration aims to pave the way for future licensing discussions and broader adoption of the ECO Synthesis platform, advancing scalable and sustainable manufacturing of therapeutic siRNA.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Codexis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN10188) on October 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}